You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

448 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Jun 2025
Drug
Other Name(s): Mekinist®
Jun 2025
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Jun 2025
Guidelines and Advice
Status: Current
ID: GL 2-33
Version: 2
Updated
Jun 2025
Les informations suivantes répondent à de nombreuses questions fréquemment posées par les médecins de première ligne au sujet du rapport d'activité...
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Updated
Jul 2025

Pages